Completing a special protocol assessment process with the FDA, Alexion Pharmaceuticals Inc. plans to begin a Phase III program of eculizumab for the chronic orphan blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH). (BioWorld Today)